文献速递生殖医学

辅助生殖技术受孕后儿童癌症风险的性别差异:一项基于登记的研究

Sex differences in childhood cancer risk following ART conception: a registry-based study.
PubMed 文献 · Hum Reprod · 2025-01-01

该研究基于挪威1984—2022年出生的2 255 025名儿童(其中53 694名经辅助生殖技术受孕),随访至2023年12月31日。结果显示,整体辅助生殖技术后癌症风险未显著升高(aHR 1.13,95%CI 0.94-1.36),但5-9岁组风险升高(aHR 1.53,95%CI 1.06-2.20),且ICSI和冻融胚胎移植后男孩风险升高。

要点

  • 辅助生殖技术受孕儿童整体癌症风险未显著升高(aHR 1.13,95%CI 0.94-1.36)。
  • 5-9岁辅助生殖技术受孕儿童癌症风险升高(aHR 1.53,95%CI 1.06-2.20),男孩更明显(aHR 1.73,95%CI 1.09-2.74)。
  • ICSI后男孩癌症风险升高(aHR 1.69,95%CI 1.18-2.42),冻融胚胎移植后男孩风险亦升高(aHR 1.79,95%CI 1.09-2.94)。

核心结论

  • 基于大型登记研究,按年龄和性别分层后,某些辅助生殖技术方式受孕的儿童中部分癌症风险升高,但在整体合并分析中未显现。
  • 作者认为这些发现需进一步研究,并考虑辅助生殖技术及不同儿童癌症可能的性别特异性机制。

研究设计与样本

  • 基于登记的队列研究,纳入1984年至2022年挪威出生的所有儿童(n=2 255 025),随访至2023年12月31日。
  • 其中53 694名儿童经辅助生殖技术(定义为IVF/ICSI)受孕,通过挪威医学出生登记处识别,并与挪威癌症登记处链接。
  • 儿童癌症定义为18岁前根据国际儿童癌症分类第三版(ICCC-3)诊断的癌症,采用Cox回归模型估计风险。

主要发现

  • 所有儿童中0.25%在18岁前被诊断为癌症。
  • 辅助生殖技术(IVF/ICSI)受孕儿童癌症累积发病率高于非辅助生殖技术受孕儿童(21.5 vs 17.5/10万人年,P=0.04),男孩经ICSI或冻融胚胎移植后尤其更高。
  • 合并所有年龄、性别和癌症类型,辅助生殖技术后癌症风险升高证据不足(aHR 1.13,95%CI 0.94-1.36)。
  • 5-9岁辅助生殖技术受孕儿童总体癌症风险升高(aHR 1.53,95%CI 1.06-2.20),男孩估计值略高(aHR 1.73,95%CI 1.09-2.74),女孩为(aHR 1.28,95%CI 0.70-2.33);5岁前或10岁后风险未升高。
  • 合并分析中ICSI后整体风险未升高;按性别分层,男孩ICSI后风险升高(aHR 1.69,95%CI 1.18-2.42),女孩未升高(aHR 0.65,95%CI 0.37-1.16);冻融胚胎移植合并风险(aHR 1.42,95%CI 0.95-2.13)由男孩风险升高驱动(aHR 1.79,95%CI 1.09-2.94),女孩无关联证据(aHR 1.01,95%CI 0.50-2.03);IVF或新鲜胚胎移植后男孩或女孩均未见风险升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 儿童癌症是罕见结局,部分癌症亚型分析可能把握度不足。
  • 作者指出研究结果需进一步研究,并考虑辅助生殖技术及不同儿童癌症可能的性别特异性机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the risk of childhood cancer following ARTs vary by sex? SUMMARY ANSWER: In this registry-based study, some childhood cancers showed positive sex- and age-specific associations in children conceived using certain ART modalities, which were not evident in overall combined analyses. WHAT IS KNOWN ALREADY: The relationship between ART and risk of childhood cancer has shown diverse outcomes in prior research. Studies examining whether there are sex differences in childhood cancer risk after ART conception are lacking. STUDY DESIGN, SIZE, DURATION: This registry-based cohort study included all children born in Norway between 1984 and 2022 (n = 2 255 025), followed until 31 December 2023. PARTICIPANTS/MATERIALS, SETTING, METHODS: Children were identified via the Medical Birth Registry of Norway, and information was extracted on whether they were conceived via ART (defined as IVF/ICSI). Of the 2 255 025 children included in the study, 53 694 were ART-conceived. Birth records were linked to the Cancer Registry of Norway. Childhood cancer was defined as a cancer diagnosis according to the International Classification of Childhood Cancer Third Edition (ICCC-3) before the age of 18 years. Cox regression models were used to estimate the age- and sex-specific risk of cancer for ART-conceived children compared to children not conceived via ART. MAIN RESULTS AND THE ROLE OF CHANCE: Among all children, 0.25% had a cancer diagnosis before the age of 18 years. The cumulative incidence of cancer was higher in children conceived by ART (IVF/ICSI) than in those not conceived via ART (21.5 vs 17.5 per 100 000 person-years, P = 0.04), and especially higher in boys conceived with ICSI or after cryopreserved embryo transfer. When combining all age groups, both sexes and all cancer types, there was little evidence of increased cancer risk with ART (adjusted hazard ratio (aHR) 1.13, 95% CI 0.94-1.36). However, differences were found when stratifying by age and sex. From age 5-9 years, ART-conceived children had a higher overall risk of cancer (aHR 1.53, 95% CI 1.06-2.20), with a slightly higher estimate in boys (aHR 1.73, 95% CI 1.09-2.74), than in girls (aHR 1.28, 95% CI 0.70-2.33). The risk was not higher up to age 5 years, or after age 10 years. In combined analyses, there was no overall increased risk after ICSI. When stratifying by sex, a higher risk was seen after ICSI for boys (aHR 1.69, 95% CI 1.18-2.42), but not for girls (aHR 0.65, 95% CI 0.37-1.16). The combined risk after cryopreservation (aHR 1.42, 95% CI 0.95-2.13) was driven by a higher risk in boys (aHR 1.79, 95% CI 1.09-2.94), while no evidence of an association was found in girls (aHR 1.01, 95% CI 0.50-2.03). No increased risk was seen with IVF or after fresh transfer for either boys or girls. LIMITATIONS, REASONS FOR CAUTION: Childhood cancer is a rare outcome, and some analyses of cancer subtypes were likely underpowered. WIDER IMPLICATIONS OF THE FINDINGS: Results from this large registry-based study suggest that addressing age- and sex-specific differences in the risk of childhood cancer following ART conception reveals increased risks for certain groups. Our findings require further study with consideration of possible underlying sex-specific mechanisms related to ART and different childhood cancers. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by: the Research Council of Norway through its Centres of Excellence Funding Scheme (project number 262700); the Norwegian Cancer Association (project number 244291); and the Norwegian Institute of Public Health. The funding agencies had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. The authors declare no conflict of interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Oakley LL, Kristjansson D, Munthe-Kaas MC, et al. Sex differences in childhood cancer risk following ART conception: a registry-based study. Hum Reprod. 2025. PMID: 39724532. doi:10.1093/humrep/deae285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。